Also earlier this month, we announced an agreement to sell our travel health business to Bavaria Nordic, which accomplishes two goals. It will help ensure that Vaxcora and VivoTeeth remain available to international travelers and other patients who need them.

Feb 27, 2023 / CEO / receipt, needs a key / Bob Cramer, CEO | earnings call 2023-02-27 | transcript 802ffaca-7841-437c-8d8f-e7f6a00e9f55 | chars 5046-5305 | segment 5

Also within commercial products business, the steady return of global travel has resulted in a stronger than anticipated demand for our typhoid vaccine, Divotif. We're also in the process of ramping up the supply chain for our cholera vaccine, Vaxcora, for the U.S. market and introducing it into select European markets. We're targeting early Q1 of 2023 to make supply available.

Nov 8, 2022 / CEO / receipt, needs a key / Bob Cramer, CEO | earnings call 2022-11-08 | transcript 04b23cb7-beca-4fa3-8e13-1a17c0ce5e10 | chars 7823-8203 | segment 8

As we're now seeing a return to global travel, we've restarted sales of VivoTeef in North America and in Europe and are in the process of relaunching VaxCora in the United States and launching Vaxcora in Europe.

Aug 1, 2022 / CEO / receipt, needs a key / Bob Cramer, CEO | earnings call 2022-08-01 | transcript 64ac572b-7019-4e0f-8a00-d516dda5fb07 | chars 8716-8927 | segment 8

Doug's portfolio includes Narcan nasal spray, travel vaccines, and other similar customer-facing products.

Nov 4, 2021 / CEO / receipt, needs a key / Bob Cramer, CEO | earnings call 2021-11-04 | transcript d20bc253-feca-427f-8f73-25e2c8f0433a | chars 9811-9917 | segment 9

As we commented earlier in the year, in late last year, because of the COVID pandemic, we're not anticipating a huge revenue contribution from the travel health business.

Apr 29, 2021 / CEO / receipt, needs a key / Bob Cramer, CEO | earnings call 2021-04-29 | transcript b1e57708-2388-4488-a1d3-5809c8d6477a | chars 31358-31528 | segment 32